Therapeutic Areas of Interest

For the most recent call for proposals, Pfizer was interested in research projects that fell within the following therapeutic areas:

Oncology

Targets/pathways that:

  • Enhance antitumor immune responses alone or in combination with standard of care.
  • Enhance immune surveillance (e.g., tumor neoAg recognition).
  • Target unique aspects of tumor or TME metabolic activity.
  • Exploit vulnerabilities in tumor heterogeneity, senescence or plasticity.
  • Promote or enable tumor-selective or -specific drug delivery or targeting.

Inflammation and Immunology

Targets/pathways that:

  • Regulate tissue-specific immune cell activation or function.
  • Exploit immune cell or lineage-specific metabolic pathways.
  • Modulate inflammation and/or tissue remodeling and repair in the context of liver fibrosis (nonalcoholic fatty liver disease [NAFLD]/nonalcoholic steatohepatitis [NASH]).
  • Promote gut epithelial barrier health and integrity.
  • Regulate antigen-specific tolerance induction and/or modulate T regulatory cells.

Cardiovascular and Metabolic Diseases

Targets/pathways that:

  • Reverse hepatic steatosis associated with NAFLD/NASH.
  • Inhibit lipolysis to treat NAFLD/NASH.
  • Reverse cachexia experienced by patients with cancer or chronic diseases, such as heart failure, chronic kidney disease and chronic obstructive pulmonary disease.
  • Reverse muscle insulin resistance in patients with type 2 diabetes mellitus.
  • Improve heart failure by specifically correcting defects in cardiac metabolism.

Rare Diseases

Targets/pathways that:

  • Represent novel targets for nonmalignant hematologic indications, including sickle cell disease and complement mediated diseases.
  • Address skeletal and cardiac muscle diseases, including Duchenne or Becker muscular dystrophies.
  • Treat repeat expansion diseases, including Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and myotonic dystrophy.

Learn more about each of these therapeutic areas of interest.